Biological age reversal, epigenetic clocks, senolytics, and anti-aging interventions
1273 articles
A Phase 1b trial shows a daily probiotic capsule may restore immunotherapy response in advanced melanoma patients who had stopped responding.
A 20,000-person study finds IgG glycan patterns track biological aging, predict mortality, and shift toward youth with interventions.
A new GLP-1 therapy engineered to cross the blood-brain barrier enters Phase II trials, targeting cognitive decline in Parkinson's and Alzheimer's.
Ossium Health is banking donor bone marrow for on-demand transplant, targeting immune aging as a future healthspan intervention.
Matter Bio files first IND for Listeria-based therapy targeting pancreatic cancer, merging oncology and longevity science.
A unified mathematical model shows stem cell division rates — not methylation errors — explain why longer-lived species age more slowly.
A muscle-secreted protein boosted by exercise declines with age — restoring it in old mice reverses muscle weakness and bone loss.
The CIMA project profiles 10M+ immune cells from 428 adults, uncovering how sex, age, and genetics shape immune function at molecular resolution.
New mouse study finds mitochondrial energy coupling stays intact with age, but subtle structural losses and sarcopenia still limit performance.
Dihydromyricetin, found in vine tea, acts as a dual senotherapeutic—suppressing SASP in fibroblasts and eliminating senescent microglia in Alzheimer's mice.
The FDA is seeking public input on repurposing approved drugs for new uses, targeting metabolic, neurodegenerative, and rare diseases.
A large retrospective study finds older men with ED face 2x higher sedative abuse risk and 50%+ greater opioid and cocaine risk.
